Association of Fc receptor-blocking antibodies and human renal-transplant survival

Alison Murray MacLeod, R.J. Mason, Keith Nicol Stewart, D.A. Power, W.G. Shewan, N. Edward, G.R.D. Catto

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Antibodies to B lymphocytes were monitored in previously transfused recipients of cadaver donor renal allografts. Forty-three patients were investigated before transplantation and in 20 of these the development of antibodies post-transplant was also studied. B lymphocyte antibodies were detected by lymphocytotoxicity and EA inhibition (EAI) against donor, normal panel, and leukemic B lymphocytes (CLL). The latter assay detects Fc receptor-blocking antibodies.

Eighty-five percent (11 of 13) of those with pretrans-plant EAI against donor lymphocytes had grafts which survived for 1 year compared with only 30% (6 of 20) of those without such antibodies (P < 0.01). Similarly 74% (14 of 19) of those with, but only 38% (9 of 24) of those without, antinormal panel EAI had grafts which survived for 1 year (P < 0.05). Seventy-seven percent (17 of 22) of those with EAI against the CLL panel, but only 29% (6 of 21) of those without, had grafts surviving for 1 year (P < 0.01). When EAI developed only post-transplant against any type of target lymphocyte, the graft had invariably failed by 1 year. If EAI had also occurred pretransplant, however, the favorable graft outcome associated with that persisted. EAI against both sets of panel lymphocytes was not directed against lymphocytes bearing any particular HLA-DR specificity, suggesting that these EA-inhibiting antibodies were not directed against classically defined HLR-DR antigens. The sera which demonstrated EAI were not necessarily the same sera which showed lymphocytotoxic activity, thus indicating the heterogeneous nature of B lymphocyte antibodies. Lymphocytotoxic antibodies were detected relatively infrequently pre- and post-transplant and no statistically significant correlation could be made with al-lograft survival.

This study demonstrates that the development of EAI post-transplant correlates with poor renal allograft survival and shows that pretransplant Fc receptor-blocking antibodies are associated with improved graft survival.
Original languageEnglish
Pages (from-to)273-279
Number of pages7
JournalTransplantation
Volume34
Issue number5
Publication statusPublished - Nov 1982

Cite this

MacLeod, A. M., Mason, R. J., Stewart, K. N., Power, D. A., Shewan, W. G., Edward, N., & Catto, G. R. D. (1982). Association of Fc receptor-blocking antibodies and human renal-transplant survival. Transplantation, 34(5), 273-279.

Association of Fc receptor-blocking antibodies and human renal-transplant survival. / MacLeod, Alison Murray; Mason, R.J. ; Stewart, Keith Nicol; Power, D.A. ; Shewan, W.G. ; Edward, N.; Catto, G.R.D. .

In: Transplantation, Vol. 34, No. 5, 11.1982, p. 273-279.

Research output: Contribution to journalArticle

MacLeod, AM, Mason, RJ, Stewart, KN, Power, DA, Shewan, WG, Edward, N & Catto, GRD 1982, 'Association of Fc receptor-blocking antibodies and human renal-transplant survival', Transplantation, vol. 34, no. 5, pp. 273-279.
MacLeod AM, Mason RJ, Stewart KN, Power DA, Shewan WG, Edward N et al. Association of Fc receptor-blocking antibodies and human renal-transplant survival. Transplantation. 1982 Nov;34(5):273-279.
MacLeod, Alison Murray ; Mason, R.J. ; Stewart, Keith Nicol ; Power, D.A. ; Shewan, W.G. ; Edward, N. ; Catto, G.R.D. . / Association of Fc receptor-blocking antibodies and human renal-transplant survival. In: Transplantation. 1982 ; Vol. 34, No. 5. pp. 273-279.
@article{0ca8a00ea2ed4926adb51a13bf5a663e,
title = "Association of Fc receptor-blocking antibodies and human renal-transplant survival",
abstract = "Antibodies to B lymphocytes were monitored in previously transfused recipients of cadaver donor renal allografts. Forty-three patients were investigated before transplantation and in 20 of these the development of antibodies post-transplant was also studied. B lymphocyte antibodies were detected by lymphocytotoxicity and EA inhibition (EAI) against donor, normal panel, and leukemic B lymphocytes (CLL). The latter assay detects Fc receptor-blocking antibodies. Eighty-five percent (11 of 13) of those with pretrans-plant EAI against donor lymphocytes had grafts which survived for 1 year compared with only 30{\%} (6 of 20) of those without such antibodies (P < 0.01). Similarly 74{\%} (14 of 19) of those with, but only 38{\%} (9 of 24) of those without, antinormal panel EAI had grafts which survived for 1 year (P < 0.05). Seventy-seven percent (17 of 22) of those with EAI against the CLL panel, but only 29{\%} (6 of 21) of those without, had grafts surviving for 1 year (P < 0.01). When EAI developed only post-transplant against any type of target lymphocyte, the graft had invariably failed by 1 year. If EAI had also occurred pretransplant, however, the favorable graft outcome associated with that persisted. EAI against both sets of panel lymphocytes was not directed against lymphocytes bearing any particular HLA-DR specificity, suggesting that these EA-inhibiting antibodies were not directed against classically defined HLR-DR antigens. The sera which demonstrated EAI were not necessarily the same sera which showed lymphocytotoxic activity, thus indicating the heterogeneous nature of B lymphocyte antibodies. Lymphocytotoxic antibodies were detected relatively infrequently pre- and post-transplant and no statistically significant correlation could be made with al-lograft survival. This study demonstrates that the development of EAI post-transplant correlates with poor renal allograft survival and shows that pretransplant Fc receptor-blocking antibodies are associated with improved graft survival.",
author = "MacLeod, {Alison Murray} and R.J. Mason and Stewart, {Keith Nicol} and D.A. Power and W.G. Shewan and N. Edward and G.R.D. Catto",
year = "1982",
month = "11",
language = "English",
volume = "34",
pages = "273--279",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Association of Fc receptor-blocking antibodies and human renal-transplant survival

AU - MacLeod, Alison Murray

AU - Mason, R.J.

AU - Stewart, Keith Nicol

AU - Power, D.A.

AU - Shewan, W.G.

AU - Edward, N.

AU - Catto, G.R.D.

PY - 1982/11

Y1 - 1982/11

N2 - Antibodies to B lymphocytes were monitored in previously transfused recipients of cadaver donor renal allografts. Forty-three patients were investigated before transplantation and in 20 of these the development of antibodies post-transplant was also studied. B lymphocyte antibodies were detected by lymphocytotoxicity and EA inhibition (EAI) against donor, normal panel, and leukemic B lymphocytes (CLL). The latter assay detects Fc receptor-blocking antibodies. Eighty-five percent (11 of 13) of those with pretrans-plant EAI against donor lymphocytes had grafts which survived for 1 year compared with only 30% (6 of 20) of those without such antibodies (P < 0.01). Similarly 74% (14 of 19) of those with, but only 38% (9 of 24) of those without, antinormal panel EAI had grafts which survived for 1 year (P < 0.05). Seventy-seven percent (17 of 22) of those with EAI against the CLL panel, but only 29% (6 of 21) of those without, had grafts surviving for 1 year (P < 0.01). When EAI developed only post-transplant against any type of target lymphocyte, the graft had invariably failed by 1 year. If EAI had also occurred pretransplant, however, the favorable graft outcome associated with that persisted. EAI against both sets of panel lymphocytes was not directed against lymphocytes bearing any particular HLA-DR specificity, suggesting that these EA-inhibiting antibodies were not directed against classically defined HLR-DR antigens. The sera which demonstrated EAI were not necessarily the same sera which showed lymphocytotoxic activity, thus indicating the heterogeneous nature of B lymphocyte antibodies. Lymphocytotoxic antibodies were detected relatively infrequently pre- and post-transplant and no statistically significant correlation could be made with al-lograft survival. This study demonstrates that the development of EAI post-transplant correlates with poor renal allograft survival and shows that pretransplant Fc receptor-blocking antibodies are associated with improved graft survival.

AB - Antibodies to B lymphocytes were monitored in previously transfused recipients of cadaver donor renal allografts. Forty-three patients were investigated before transplantation and in 20 of these the development of antibodies post-transplant was also studied. B lymphocyte antibodies were detected by lymphocytotoxicity and EA inhibition (EAI) against donor, normal panel, and leukemic B lymphocytes (CLL). The latter assay detects Fc receptor-blocking antibodies. Eighty-five percent (11 of 13) of those with pretrans-plant EAI against donor lymphocytes had grafts which survived for 1 year compared with only 30% (6 of 20) of those without such antibodies (P < 0.01). Similarly 74% (14 of 19) of those with, but only 38% (9 of 24) of those without, antinormal panel EAI had grafts which survived for 1 year (P < 0.05). Seventy-seven percent (17 of 22) of those with EAI against the CLL panel, but only 29% (6 of 21) of those without, had grafts surviving for 1 year (P < 0.01). When EAI developed only post-transplant against any type of target lymphocyte, the graft had invariably failed by 1 year. If EAI had also occurred pretransplant, however, the favorable graft outcome associated with that persisted. EAI against both sets of panel lymphocytes was not directed against lymphocytes bearing any particular HLA-DR specificity, suggesting that these EA-inhibiting antibodies were not directed against classically defined HLR-DR antigens. The sera which demonstrated EAI were not necessarily the same sera which showed lymphocytotoxic activity, thus indicating the heterogeneous nature of B lymphocyte antibodies. Lymphocytotoxic antibodies were detected relatively infrequently pre- and post-transplant and no statistically significant correlation could be made with al-lograft survival. This study demonstrates that the development of EAI post-transplant correlates with poor renal allograft survival and shows that pretransplant Fc receptor-blocking antibodies are associated with improved graft survival.

M3 - Article

VL - 34

SP - 273

EP - 279

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 5

ER -